InvestSMART

Noxopharm Limited (ASX:NOX)

ALERT: Price-sensitive ASX Announcement for NOX
Current share price for NOX : $0.072 -0.023 (-24.21%)+
Announcement
Release
26 Aug 2026 8:06AM
Price at Release
$0.095
Full Release
download
Summary
Noxopharm Limited has announced promising new preclinical data from their Sofra™ technology, which demonstrates potential significant advances in immuno-oncology. The study, in collaboration with the Hudson Institute of Medical Research, revealed that the TLR8-amplifying oligonucleotide could significantly activate immune cells when combined with dying cancer cells, an effect not seen with the oligonucleotide absent. This discovery supports the potential of Sofra™ technology to complement traditional cancer treatments such as chemotherapy and radiotherapy and advances Noxopharm’s oncology program towards in vivo proof-of-concept trials. Noxopharm aims to reveal cancer presence to the immune system, aligning with the growing field of cancer immunotherapy.
Key Points
  • Noxopharm Limited has released new preclinical data supporting its immuno-oncology approach.
  • The company's Sofra™ technology has shown the ability to activate immune cells in response to dying cancer cells.
  • Significant immune activation was observed when combining dying cancer cells with a TLR8-amplifying oligonucleotide.
  • This supports the potential of Sofra™ technology to enhance cancer treatments such as chemotherapy and radiotherapy.
  • Noxopharm's findings advance their oncology program towards in vivo proof-of-concept studies.
  • The study, conducted with the Hudson Institute of Medical Research, highlights new activation mechanisms via TLR8 in macrophages.
  • The data provides further validation of Noxopharm’s Sofra™ platform as a promising cancer treatment strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.